Heart Attack / ACS

We have participated in more than 1,200 clinical research trials (130 active trials) and have introduced most of the new techniques in cardiovascular medicine over the past 20 years.

Clinical Trials: Heart Attack / ACS

Description

A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults Who Have Left Ventricular Systolic Dysfunction Following Myocardial Infarction

Investigator(s): Kereiakes

Enrolling

A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial

Investigator(s): Kereiakes

Enrolling

Investigator(s): Satya Shreenivas, MD

Enrolling

A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.

Investigator(s): Sarembock

Follow up only

Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With an Anterior Myocardial Infarction and Ischemic Left Ventricular Dysfunction

Investigator(s): Kereiakes

Follow up only

A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Investigator(s): Kereiakes

Follow up only

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome

Investigator(s): Sarembock

Follow up only

A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome

Investigator(s): Sarembock

Follow up only

A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 [SOLID-TIMI 52] Trial)Study Identifier: SB480848/033

Investigator(s): Kereiakes

Follow up only

TOTAL Pilot Trial – A randomized trial of routine aspiration ThrOmbecTomy with PCI versus PCI ALone in patients with STEMI undergoing primary PCI

Investigator(s): Sarembock

Follow up only